valacyclovir + celecoxib + nirmatrelvir + ritonavir

valacyclovir + celecoxib + nirmatrelvir + ritonavir is an investigational combination regimen being developed by PridCor Therapeutics for the treatment of Long COVID (post-acute sequelae of COVID-19). The regimen, evaluated in the Phase 2 SHIELD trial (NCT07597902), is designed to simultaneously address two proposed biological drivers of Long COVID: persistent SARS-CoV-2 infection and the reactivation of latent herpesviruses (such as Epstein-Barr virus). It combines IMC-2—a proprietary fixed-dose combination of the antiviral valacyclovir and the selective COX-2 inhibitor celecoxib—with a pulsed course of the SARS-CoV-2 protease inhibitor nirmatrelvir/ritonavir (Paxlovid). Within this regimen, valacyclovir suppresses herpesvirus replication, celecoxib reduces COX-2-mediated inflammation and herpesvirus reactivation, nirmatrelvir inhibits the SARS-CoV-2 main protease (3CLpro) to halt viral replication, and ritonavir acts as a pharmacokinetic booster by inhibiting CYP3A4-mediated metabolism of nirmatrelvir.